Moleculin Biotech, Inc.
MBRX
$2.34
-$0.10-4.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 12.11% | 2.68% | |||
| Depreciation & Amortization | -57.14% | -27.59% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 27.55% | 3.23% | |||
| Operating Income | -27.55% | -3.23% | |||
| Income Before Tax | 161.23% | -47.01% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 161.23% | -47.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 161.23% | -47.01% | |||
| EBIT | -27.55% | -3.23% | |||
| EBITDA | -27.87% | -3.35% | |||
| EPS Basic | 140.53% | 37.60% | |||
| Normalized Basic EPS | 140.81% | 37.60% | |||
| EPS Diluted | 140.53% | 37.60% | |||
| Normalized Diluted EPS | 140.81% | 37.60% | |||
| Average Basic Shares Outstanding | 50.05% | 135.62% | |||
| Average Diluted Shares Outstanding | 50.05% | 135.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||